KM Research Hub
← 返回论文库
待处理 入排:排除 图源:待检查

Lepalvir: Biomaterial efficacy and safety for patients with acute ischemic stroke.

Benke Zhao, Kai Dong, Qingfeng Ma, Yutong Ma, Aihong Guo, Runhui Li, Jianghua Liu, Hong Zhang, Qingcheng Yang, Wei Yue, Yi Sui, Yuan Wang, Haiqing Song

iScience 28(2) 111621

PMID39925427
PMCIDPMC11804740
DOI10.1016/j.isci.2024.111621
发表日期2025-02-10
摘要

摘要

Lepalvir, derived from inflamed rabbit skin inoculated with vaccinia virus, has potential neuroprotective and anti-inflammatory effects. We conducted a phase II, multicenter, randomized, blind, placebo-controlled trial investigating the efficacy and safety of Lepalvir for acute ischemic stroke (AIS). Participants aged 18-80 years with AIS in the anterior circulation and a National Institutes of Health Stroke Scale (NIHSS) score of 4-24 within 48 h post-onset were randomized to receive high-dose (192U), low-dose (96U) Lepalvir, or saline placebo for 14 days. The primary outcome was the proportion of patients achieving a modified Rankin Scale (mRS) score ≤ 1 at day 90 (D90) post-randomization. Among 238 patients, no significant difference in mRS score at D90 was observed across groups, yet a higher percentage in the high-dose group achieved a mRS score ≤ 1 at D90, compared to the control and low-dose group. No significant safety concerns were noted. While functional improvement was not significantly different at D90, Lepalvir showed a favorable safety profile and potential at the higher dosage, warranting further phase III investigation.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。